1. Gene Therapy Products


Engensis (VM202) is an innovative gene therapy
drug that provides fundamental treatment through
tissue regeneration.​





Diabetic Foot Ulcer(DFU)​

Diabetic foot ulcers (DFU) is chronic, non-healing foot ulcers caused by impediment of the wound-healing process, a major complication of both diabetes and peripheral arterial disease (PAD). Over 6.5 million people in the US alone have chronic, non-healing foot ulcers; many of them also have peripheral neuropathy, which results in numbness or pain in the legs and arms. 25% of wounds progress to the extent that amputation is required. Current treatments are limited to wound care dressings or pain management.

Engensis (VM202) is currently under development as a possible treatment for chronic DFU with the hope to potentially heal the ulcer by supplying sufficient blood through new blood vessel formation around occluded or narrowed blood vessels towards the lower extremities.​

Main symptoms​

  • Paresthesia​

  • Foot ulcer​

Status of clinical trials


Indication Pre-clinical Phase 1 Phase 2 Phase 3
Diabetic Foot Ulcer(DFU)​ US